Karyopharm Therapeutics (KPTI) EBT (2012 - 2025)

Karyopharm Therapeutics has reported EBT for 14 years, with the latest figure at $90.1 million in Q4 2025.

• For the quarter ending Q4 2025, EBT rose 97.82% year-over-year to $90.1 million; the trailing twelve-month figure through Dec 2025 stood at -$3.6 million (down 4616.25% YoY), and the FY2025 full-year result was -$3.6 million, down 4616.25% from the prior year.
• EBT for Q4 2025 stood at $90.1 million, up from -$33.1 million in the prior quarter.
• The five-year high for EBT was $90.1 million in Q4 2025, with the low at -$57.3 million in Q1 2021.
• Historically, EBT has averaged -$20.2 million across 5 years, with a median of -$35.4 million in 2022.
• Annual changes were most pronounced in 2024 — EBT surged 209.23% — and 2025, when it tumbled 255.97%.
• Karyopharm Therapeutics' EBT stood at $68.7 million in 2021, then plunged by 155.98% to -$38.4 million in 2022, then declined by 8.52% to -$41.7 million in 2023, then surged by 209.23% to $45.6 million in 2024, then jumped by 97.82% to $90.1 million in 2025.
• The last three EBT figures came in at $90.1 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.2 million (Q2 2025), per Business Quant data.